Edwards Lifesciences (NYSE:EW) Releases Q1 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.580-0.640 for the period, compared to the consensus earnings per share estimate of 0.590. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Edwards Lifesciences also updated its FY 2025 guidance to 2.400-2.500 EPS.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.15 during midday trading on Tuesday, reaching $70.95. The company had a trading volume of 3,405,627 shares, compared to its average volume of 4,396,275. The company has a market capitalization of $41.85 billion, a P/E ratio of 10.24, a P/E/G ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The firm’s fifty day simple moving average is $72.46 and its 200-day simple moving average is $69.26. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. As a group, equities analysts anticipate that Edwards Lifesciences will post 2.56 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. Citigroup raised their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Wolfe Research downgraded shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a report on Thursday, January 16th. Barclays raised their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Truist Financial restated a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $79.19.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,000 shares of company stock worth $547,430. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.